Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Boston Scientific price target raised to $53 from $48 at Needham » 08:41
02/02/23
02/02
08:41
02/02/23
08:41
BSX

Boston Scientific

$47.54 /

+1.29 (+2.79%)

Needham analyst Mike…

Needham analyst Mike Matson raised the firm's price target on Boston Scientific to $53 from $48 and keeps a Buy rating on the shares after its mixed Q4 results. An unplanned reserve in connection with a payback provision in Italy reduced Q4 revenue by $60M and EPS by 4c, and BSX would have beaten consensus without this, the analyst tells investors in a research note. The firm adds that the quarter supports its view that Boston Scientific is more insulated from macro headwinds and can sustain higher growth than most of its peers.

ShowHide Related Items >><<
BSX Boston Scientific
$47.54 /

+1.29 (+2.79%)

BSX Boston Scientific
$47.54 /

+1.29 (+2.79%)

02/01/23 Stifel
Boston Scientific price target raised to $52 from $50 at Stifel
02/01/23 Piper Sandler
Piper remains bullish on Boston Scientific, says guidance likely conservative
01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
BSX Boston Scientific
$47.54 /

+1.29 (+2.79%)

BSX Boston Scientific
$47.54 /

+1.29 (+2.79%)

BSX Boston Scientific
$47.54 /

+1.29 (+2.79%)

Wednesday
Recommendations
Boston Scientific price target raised to $52 from $50 at Stifel » 14:28
02/01/23
02/01
14:28
02/01/23
14:28
BSX

Boston Scientific

$46.98 /

+0.73 (+1.58%)

Stifel analyst Rick Wise…

Stifel analyst Rick Wise raised the firm's price target on Boston Scientific to $52 from $50 and keeps a Buy rating on the shares. While the surprising Italian "payment provision" optics complicated the company's Q4 reported performance, organic performance was "excellent" across all product lines, the analyst tells investors in a research note. The firm added that Boston Scientific has important product launches and multiple potentially-positive data catalysts ahead, and that such factors along with possibly easing macro pressures could help prove initial 2023 guidance conservative.

ShowHide Related Items >><<
BSX Boston Scientific
$46.98 /

+0.73 (+1.58%)

BSX Boston Scientific
$46.98 /

+0.73 (+1.58%)

02/01/23 Piper Sandler
Piper remains bullish on Boston Scientific, says guidance likely conservative
01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
BSX Boston Scientific
$46.98 /

+0.73 (+1.58%)

BSX Boston Scientific
$46.98 /

+0.73 (+1.58%)

BSX Boston Scientific
$46.98 /

+0.73 (+1.58%)

Recommendations
Piper remains bullish on Boston Scientific, says guidance likely conservative » 13:05
02/01/23
02/01
13:05
02/01/23
13:05
BSX

Boston Scientific

$46.68 /

+0.43 (+0.93%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien notes that Boston Scientific reported Q4 results that beat expectations on the top- and bottom lines when adjusting for an unexpected revenue reserve the company took. The cardiology franchise remains strong and urology continues to exceed expectations as well, the firm says. Piper also notes that management provided 2023 revenue and EPS guidance that was right in-line with the Street, but it suspects they are being conservative with their outlook given the strong, broad-based momentum in the business. In aggregate, Boston Scientific remains a high-quality growth asset and the firm's favorite diversified large cap. Piper has an Overweight rating on the shares with a price target of $50.

ShowHide Related Items >><<
BSX Boston Scientific
$46.68 /

+0.43 (+0.93%)

BSX Boston Scientific
$46.68 /

+0.43 (+0.93%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
BSX Boston Scientific
$46.68 /

+0.43 (+0.93%)

BSX Boston Scientific
$46.68 /

+0.43 (+0.93%)

BSX Boston Scientific
$46.68 /

+0.43 (+0.93%)

Earnings
Boston Scientific sees FY23 adjusted EPS $1.86-$1.93, consensus $1.93 » 06:37
02/01/23
02/01
06:37
02/01/23
06:37
BSX

Boston Scientific

$46.25 /

+0.445 (+0.97%)

Sees FY23 revenue up…

Sees FY23 revenue up 5%-7%, consensus $13.64B. The company said, "The company estimates net sales growth for the full year 2023, versus the prior year period, to be in a range of approximately 5 to 7 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93."

ShowHide Related Items >><<
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

Earnings
Boston Scientific sees Q1 adjusted EPS 42c-44c, consensus 44c » 06:35
02/01/23
02/01
06:35
02/01/23
06:35
BSX

Boston Scientific

$46.25 /

+0.445 (+0.97%)

Sees Q1 revenue up 3%-5%,…

Sees Q1 revenue up 3%-5%, consensus $3.17B. The company said, "The company estimates net sales growth for the first quarter of 2023, versus the prior year period, to be in a range of approximately 3 to 5 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. First quarter organic guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.23 to $0.26 and adjusted EPS, excluding certain charges (credits) of $0.42 to $0.44."

ShowHide Related Items >><<
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

Earnings
Boston Scientific reports Q4 adjusted EPS 45c, consensus 47c » 06:33
02/01/23
02/01
06:33
02/01/23
06:33
BSX

Boston Scientific

$46.25 /

+0.445 (+0.97%)

Reports Q4 revenue…

Reports Q4 revenue $3.24B, consensus $3.24B. "Our global team continues living our mission to transform lives, and I'm proud of the results we achieved in the fourth quarter and throughout 2022," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "In the year ahead we remain committed to our goals of delivering new, meaningful innovations to benefit patients globally while continuing to deliver differentiated financial performance."

ShowHide Related Items >><<
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

Tuesday
Earnings
Notable companies reporting before tomorrow's open » 20:25
01/31/23
01/31
20:25
01/31/23
20:25
TMO

Thermo Fisher

$570.40 /

+6.335 (+1.12%)

, TMUS

T-Mobile

$149.39 /

+2.47 (+1.68%)

, MO

Altria Group

$45.05 /

+0.56 (+1.26%)

, BSX

Boston Scientific

$46.25 /

+0.445 (+0.97%)

, HUM

Humana

$511.80 /

+26.74 (+5.51%)

, ABC

AmerisourceBergen

$168.98 /

+3.595 (+2.17%)

, FTV

Fortive

$68.04 /

+1.795 (+2.71%)

, DT

Dynatrace

$38.38 /

+0.345 (+0.91%)

, PTON

Peloton

$12.92 /

+0.405 (+3.24%)

, EAT

Brinker

$39.45 /

+0.85 (+2.20%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Thermo Fisher (TMO), consensus $5.19... T-Mobile (TMUS), consensus $1.10... Altria (MO), consensus $1.17... Boston Scientific (BSX), consensus 47c... Humana (HUM), consensus $1.46... AmerisourceBergen (ABC), consensus $2.63... Fortive (FTV), consensus 84c... Dynatrace (DT), consensus 21c... Peloton (PTON), consensus (64c)... Brinker (EAT), consensus 52c.

ShowHide Related Items >><<
TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

PTON Peloton
$12.92 /

+0.405 (+3.24%)

MO Altria Group
$45.05 /

+0.56 (+1.26%)

HUM Humana
$511.80 /

+26.74 (+5.51%)

EAT Brinker
$39.45 /

+0.85 (+2.20%)

DT Dynatrace
$38.38 /

+0.345 (+0.91%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

ABC AmerisourceBergen
$168.98 /

+3.595 (+2.17%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

01/24/23 Barclays
Thermo Fisher price target raised to $630 from $570 at Barclays
01/03/23 Wells Fargo
Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
12/13/22 Deutsche Bank
Thermo Fisher initiated with a Buy at Deutsche Bank
12/06/22 RBC Capital
Thermo Fisher initiated with an Outperform at RBC Capital
TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

01/17/23 KeyBanc
Cogent price target raised to $71 from $64 at KeyBanc
01/13/23 Truist
American Tower price target lowered to $275 from $325 at Truist
01/05/23 JPMorgan
T-Mobile remains a top pick after preannouncement at JPMorgan
01/03/23 Wolfe Research
T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research
MO Altria Group
$45.05 /

+0.56 (+1.26%)

11/10/22 UBS
UBS downgrades Altria to Sell on consumer trade down risk
11/10/22 UBS
Altria Group downgraded to Sell from Neutral at UBS
11/02/22 Morgan Stanley
Philip Morris price target raised to $109 from $102 at Morgan Stanley
10/28/22 Stifel
Altria JV news trumps 'rare' EPS miss, says Stifel
BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
HUM Humana
$511.80 /

+26.74 (+5.51%)

01/31/23 JPMorgan
Medicare Advantage final rule more favorable than feared, says JPMorgan
01/30/23 Cowen
Evolent Health price target raised to $59 from $57 at Cowen
12/27/22 Piper Sandler
Piper views TriCare T-5 contract awards as neutral for Accolade
12/23/22 Wells Fargo
Humana keeps TRICARE East, Centene loses West region, says Wells Fargo
ABC AmerisourceBergen
$168.98 /

+3.595 (+2.17%)

01/31/23 UBS
AmerisourceBergen price target raised to $190 from $184 at UBS
01/31/23 Evercore ISI
AmerisourceBergen resumed with an Outperform at Evercore ISI
01/12/23 Argus
AmerisourceBergen price target raised to $190 from $170 at Argus
01/11/23 Baird
AmerisourceBergen price target raised to $199 from $195 at Baird
FTV Fortive
$68.04 /

+1.795 (+2.71%)

01/13/23 Mizuho
Fortive price target raised to $63 from $60 at Mizuho
12/09/22 Citi
Fortive price target raised to $77 from $73 at Citi
10/12/22 Morgan Stanley
Fortive upgraded to Overweight at Morgan Stanley on execution, resilience
10/12/22 Morgan Stanley
Fortive upgraded to Overweight from Equal Weight at Morgan Stanley
DT Dynatrace
$38.38 /

+0.345 (+0.91%)

01/10/23 Barclays
Dynatrace downgraded to Equal Weight from Overweight at Barclays
01/09/23 Truist
Dynatrace price target lowered to $45 from $50 at Truist
01/03/23 Wells Fargo
Dynatrace price target raised to $50 from $45 at Wells Fargo
12/15/22 Wedbush
Wedbush initiates Dynatrace with a Neutral and $35 price target
PTON Peloton
$12.92 /

+0.405 (+3.24%)

01/30/23 Citi
Peloton promotions drove improved traffic trends, says Citi
01/24/23 MKM Partners
MKM Partners positive on Peloton heading into earnings
01/24/23 Baird
Peloton downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Peloton downgraded to Market Perform from Outperform at Cowen
EAT Brinker
$39.45 /

+0.85 (+2.20%)

01/24/23 Deutsche Bank
Brinker price target raised to $38 from $34 at Deutsche Bank
01/05/23 Barclays
Brinker price target lowered to $30 from $31 at Barclays
12/21/22 Jefferies
Brinker downgraded to Hold from Buy at Jefferies
12/12/22 Goldman Sachs
Brinker downgraded to Sell from Neutral at Goldman Sachs
TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

PTON Peloton
$12.92 /

+0.405 (+3.24%)

MO Altria Group
$45.05 /

+0.56 (+1.26%)

HUM Humana
$511.80 /

+26.74 (+5.51%)

FTV Fortive
$68.04 /

+1.795 (+2.71%)

EAT Brinker
$39.45 /

+0.85 (+2.20%)

DT Dynatrace
$38.38 /

+0.345 (+0.91%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

ABC AmerisourceBergen
$168.98 /

+3.595 (+2.17%)

  • 09
    Dec
  • 08
    Nov
TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

PTON Peloton
$12.92 /

+0.405 (+3.24%)

MO Altria Group
$45.05 /

+0.56 (+1.26%)

HUM Humana
$511.80 /

+26.74 (+5.51%)

ABC AmerisourceBergen
$168.98 /

+3.595 (+2.17%)

TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

PTON Peloton
$12.92 /

+0.405 (+3.24%)

MO Altria Group
$45.05 /

+0.56 (+1.26%)

HUM Humana
$511.80 /

+26.74 (+5.51%)

FTV Fortive
$68.04 /

+1.795 (+2.71%)

EAT Brinker
$39.45 /

+0.85 (+2.20%)

DT Dynatrace
$38.38 /

+0.345 (+0.91%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

ABC AmerisourceBergen
$168.98 /

+3.595 (+2.17%)

TMUS T-Mobile
$149.39 /

+2.47 (+1.68%)

TMO Thermo Fisher
$570.40 /

+6.335 (+1.12%)

PTON Peloton
$12.92 /

+0.405 (+3.24%)

MO Altria Group
$45.05 /

+0.56 (+1.26%)

HUM Humana
$511.80 /

+26.74 (+5.51%)

BSX Boston Scientific
$46.25 /

+0.445 (+0.97%)

Earnings
Notable companies reporting before tomorrow's open » 13:21
01/31/23
01/31
13:21
01/31/23
13:21
TMO

Thermo Fisher

$563.16 /

-0.905 (-0.16%)

, TMUS

T-Mobile

$149.52 /

+2.6 (+1.77%)

, MO

Altria Group

$44.73 /

+0.24 (+0.54%)

, BSX

Boston Scientific

$45.97 /

+0.165 (+0.36%)

, HUM

Humana

$508.55 /

+23.49 (+4.84%)

, ABC

AmerisourceBergen

$167.82 /

+2.435 (+1.47%)

, FTV

Fortive

$67.51 /

+1.27 (+1.92%)

, DT

Dynatrace

$38.07 /

+0.03 (+0.08%)

, PTON

Peloton

$12.94 /

+0.43 (+3.44%)

, EAT

Brinker

$39.13 /

+0.53 (+1.37%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Thermo Fisher (TMO), consensus $5.19... T-Mobile (TMUS), consensus $1.10... Altria (MO), consensus $1.17... Boston Scientific (BSX), consensus 47c... Humana (HUM), consensus $1.46... AmerisourceBergen (ABC), consensus $2.63... Fortive (FTV), consensus 84c... Dynatrace (DT), consensus 21c... Peloton (PTON), consensus (64c)... Brinker (EAT), consensus 52c.

ShowHide Related Items >><<
TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

PTON Peloton
$12.94 /

+0.43 (+3.44%)

MO Altria Group
$44.73 /

+0.24 (+0.54%)

HUM Humana
$508.55 /

+23.49 (+4.84%)

EAT Brinker
$39.13 /

+0.53 (+1.37%)

DT Dynatrace
$38.07 /

+0.03 (+0.08%)

BSX Boston Scientific
$45.97 /

+0.165 (+0.36%)

ABC AmerisourceBergen
$167.82 /

+2.435 (+1.47%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

01/24/23 Barclays
Thermo Fisher price target raised to $630 from $570 at Barclays
01/03/23 Wells Fargo
Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
12/13/22 Deutsche Bank
Thermo Fisher initiated with a Buy at Deutsche Bank
12/06/22 RBC Capital
Thermo Fisher initiated with an Outperform at RBC Capital
TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

01/17/23 KeyBanc
Cogent price target raised to $71 from $64 at KeyBanc
01/13/23 Truist
American Tower price target lowered to $275 from $325 at Truist
01/05/23 JPMorgan
T-Mobile remains a top pick after preannouncement at JPMorgan
01/03/23 Wolfe Research
T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research
MO Altria Group
$44.73 /

+0.24 (+0.54%)

11/10/22 UBS
UBS downgrades Altria to Sell on consumer trade down risk
11/10/22 UBS
Altria Group downgraded to Sell from Neutral at UBS
11/02/22 Morgan Stanley
Philip Morris price target raised to $109 from $102 at Morgan Stanley
10/28/22 Stifel
Altria JV news trumps 'rare' EPS miss, says Stifel
BSX Boston Scientific
$45.97 /

+0.165 (+0.36%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
HUM Humana
$508.55 /

+23.49 (+4.84%)

01/31/23 JPMorgan
Medicare Advantage final rule more favorable than feared, says JPMorgan
01/30/23 Cowen
Evolent Health price target raised to $59 from $57 at Cowen
12/27/22 Piper Sandler
Piper views TriCare T-5 contract awards as neutral for Accolade
12/23/22 Wells Fargo
Humana keeps TRICARE East, Centene loses West region, says Wells Fargo
ABC AmerisourceBergen
$167.82 /

+2.435 (+1.47%)

01/31/23 UBS
AmerisourceBergen price target raised to $190 from $184 at UBS
01/31/23 Evercore ISI
AmerisourceBergen resumed with an Outperform at Evercore ISI
01/12/23 Argus
AmerisourceBergen price target raised to $190 from $170 at Argus
01/11/23 Baird
AmerisourceBergen price target raised to $199 from $195 at Baird
FTV Fortive
$67.51 /

+1.27 (+1.92%)

01/13/23 Mizuho
Fortive price target raised to $63 from $60 at Mizuho
12/09/22 Citi
Fortive price target raised to $77 from $73 at Citi
10/12/22 Morgan Stanley
Fortive upgraded to Overweight at Morgan Stanley on execution, resilience
10/12/22 Morgan Stanley
Fortive upgraded to Overweight from Equal Weight at Morgan Stanley
DT Dynatrace
$38.07 /

+0.03 (+0.08%)

01/10/23 Barclays
Dynatrace downgraded to Equal Weight from Overweight at Barclays
01/09/23 Truist
Dynatrace price target lowered to $45 from $50 at Truist
01/03/23 Wells Fargo
Dynatrace price target raised to $50 from $45 at Wells Fargo
12/15/22 Wedbush
Wedbush initiates Dynatrace with a Neutral and $35 price target
PTON Peloton
$12.94 /

+0.43 (+3.44%)

01/30/23 Citi
Peloton promotions drove improved traffic trends, says Citi
01/24/23 MKM Partners
MKM Partners positive on Peloton heading into earnings
01/24/23 Baird
Peloton downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Peloton downgraded to Market Perform from Outperform at Cowen
EAT Brinker
$39.13 /

+0.53 (+1.37%)

01/24/23 Deutsche Bank
Brinker price target raised to $38 from $34 at Deutsche Bank
01/05/23 Barclays
Brinker price target lowered to $30 from $31 at Barclays
12/21/22 Jefferies
Brinker downgraded to Hold from Buy at Jefferies
12/12/22 Goldman Sachs
Brinker downgraded to Sell from Neutral at Goldman Sachs
TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

PTON Peloton
$12.94 /

+0.43 (+3.44%)

MO Altria Group
$44.73 /

+0.24 (+0.54%)

HUM Humana
$508.55 /

+23.49 (+4.84%)

FTV Fortive
$67.51 /

+1.27 (+1.92%)

EAT Brinker
$39.13 /

+0.53 (+1.37%)

DT Dynatrace
$38.07 /

+0.03 (+0.08%)

BSX Boston Scientific
$45.97 /

+0.165 (+0.36%)

ABC AmerisourceBergen
$167.82 /

+2.435 (+1.47%)

  • 09
    Dec
  • 08
    Nov
TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

PTON Peloton
$12.94 /

+0.43 (+3.44%)

MO Altria Group
$44.73 /

+0.24 (+0.54%)

HUM Humana
$508.55 /

+23.49 (+4.84%)

ABC AmerisourceBergen
$167.82 /

+2.435 (+1.47%)

TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

PTON Peloton
$12.94 /

+0.43 (+3.44%)

MO Altria Group
$44.73 /

+0.24 (+0.54%)

HUM Humana
$508.55 /

+23.49 (+4.84%)

FTV Fortive
$67.51 /

+1.27 (+1.92%)

EAT Brinker
$39.13 /

+0.53 (+1.37%)

DT Dynatrace
$38.07 /

+0.03 (+0.08%)

BSX Boston Scientific
$45.97 /

+0.165 (+0.36%)

ABC AmerisourceBergen
$167.82 /

+2.435 (+1.47%)

TMUS T-Mobile
$149.52 /

+2.6 (+1.77%)

TMO Thermo Fisher
$563.16 /

-0.905 (-0.16%)

PTON Peloton
$12.94 /

+0.43 (+3.44%)

MO Altria Group
$44.73 /

+0.24 (+0.54%)

HUM Humana
$508.55 /

+23.49 (+4.84%)

BSX Boston Scientific
$45.97 /

+0.165 (+0.36%)

Over a week ago
Downgrade
Apollo Endosurgery downgraded to Market Perform from Outperform at Cowen » 07:16
01/23/23
01/23
07:16
01/23/23
07:16
APEN

Apollo Endosurgery

$9.83 /

-0.015 (-0.15%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings downgraded Apollo Endosurgery (APEN) to Market Perform from Outperform with a price target of $10, down from $13, after Boston Scientific (BSX) announced a deal to acquire the company for $10 per share in cash back in November.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$9.83 /

-0.015 (-0.15%)

APEN Apollo Endosurgery
$9.83 /

-0.015 (-0.15%)

01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
11/30/22 Lake Street
Apollo Endosurgery downgraded to Hold from Buy at Lake Street
11/29/22 Piper Sandler
Piper says Apollo Endosurgery can help Boston Scientific expand ELS franchise
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
APEN Apollo Endosurgery
$9.83 /

-0.015 (-0.15%)

Options
Boston Scientific put volume heavy and directionally bearish » 12:15
01/11/23
01/11
12:15
01/11/23
12:15
BSX

Boston Scientific

$44.71 /

-1.36 (-2.95%)

Bearish flow noted in…

Bearish flow noted in Boston Scientific with 4,037 puts trading, or 6x expected. Most active are Jan-23 44 puts and Jan-23 47 calls, with total volume in those strikes near 4,000 contracts. The Put/Call Ratio is 4.60, while ATM IV is up over 1 point on the day. Earnings are expected on February 1st.

ShowHide Related Items >><<
BSX Boston Scientific
$44.71 /

-1.36 (-2.95%)

BSX Boston Scientific
$44.71 /

-1.36 (-2.95%)

01/04/23 Barclays
Boston Scientific price target raised to $53 from $49 at Barclays
01/03/23 Stifel
Apollo Endosurgery downgraded to Hold from Buy at Stifel
12/22/22 Mizuho
Boston Scientific initiated with a Neutral at Mizuho
12/20/22 Citi
Boston Scientific resumed with a Buy at Citi
BSX Boston Scientific
$44.71 /

-1.36 (-2.95%)

BSX Boston Scientific
$44.71 /

-1.36 (-2.95%)

BSX Boston Scientific
$44.71 /

-1.36 (-2.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.